Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF APRIL 10, 2015 FBO #4885
SOLICITATION NOTICE

A -- Sole Source - Research and Development

Notice Date
4/8/2015
 
Notice Type
Combined Synopsis/Solicitation
 
NAICS
541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
 
ZIP Code
20857-0001
 
Solicitation Number
FDA-SS1147879
 
Archive Date
4/30/2015
 
Point of Contact
Natalie Mitchell, Phone: 2404027601
 
E-Mail Address
natalie.mitchell@fda.hhs.gov
(natalie.mitchell@fda.hhs.gov)
 
Small Business Set-Aside
N/A
 
Description
FDA-SS-1147879 The U.S. Food & Drug Administration intends to issue a sole-source modification to Summer Productions Inc. under Contract No. HHSF223201400134C. The estimated amount of this modification is around $63,504.00 and it will extend the contract completion date by six months. The above contract at $175,271.00 was awarded to Summer Productions Inc. on September 18, 2014 through FDA's Broad Agency Announcement for research and development to support regulatory science and innovation, solicitation number FDABAA-13-00119. The purpose of the contract was to understand the FDA's brand awareness among physicians; to understand how physicians access information from the FDA and what the preferred strategies are for physicians to receive regulatory and scientific information from the agency; to evaluate the effectiveness of information related to the FDA and drugs that physicians receive from the agency; and to recommend improvements in the strategies and platforms that the FDA uses to communicate to physicians Purpose of Modification: In the original statement of work, the offeror proposed the production, dissemination, and review of physician focus groups to learn about their interactions with CDER and their understanding of its regulatory mission. Upon further review of its original statement of work and research plan, one additional focus group with physicians in New York and three additional focus groups comprised of pharmacists are needed. The purpose of adding an additional focus group of physicians in New York is to capture a more complete and representative view of physician opinion across the United States. As the most populated city in the United States with a large diverse medical practice, New York could offer insights unique to every other city the offeror has previously sampled. The purpose of adding pharmacist focus groups is to augment the information that has already been gleaned from the physician groups. The physician focus groups have helped FDA understand how different healthcare professionals access information differently. The offeror's preliminary findings show that some of FDA materials and assets used with physicians may be targeted more towards pharmacists in their practice. This has allowed the offeror to develop a hypothesis that other health prescribers, especially pharmacists, access the Agency's regulatory information in different ways. Adding three pharmacist groups will ensure that FDA understands how it communicates to an overlooked partner of the healthcare continuum. Award will be made in accordance with Federal Acquisition Regulation (FAR) Part 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements using Simplified Acquisition Procedures per FAR Part 13. This notice of intent is not a request for competitive quotes. However, all responsible sources may submit a capability statement within Seven calendar days after the publication of this synopsis which shall be considered by the agency. Responses received after Seven days or without the required information may not be considered. A determination by the Government not to compete as a result of information received is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. For information concerning this acquisition, contact Natalie Mitchell, Contract Specialist at Natalie.Mitchell@fda.hhs.gov
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-SS1147879/listing.html)
 
Record
SN03693733-W 20150410/150408235501-4b09a0aa9b9fc032ad8d4323469217d4 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.